What is it about?
The falling costs, the increasing validity and the short time for providing sequencing data with next-generation sequencing platforms [14–16] have moved research into genome sequencing and transcriptome analysis in patients’ tissue samples relating genome data with clinical phenotypes
Featured Image
Why is it important?
Without deeper insights into how driver mutations and epigenetic changes escape protective functional regulatory mechanisms leading to cancer, progress in biomedical science and healthcare will continue to be slow.
Perspectives
Progress is required in understanding physical and functional networks of interacting DNA, noncoding RNAs including miRNAs, proteins and other molecules. Hopefully, step-by-step advances and insights into transcriptome, proteome, epigenome and interactome analysis will lead to network medicine
Dr Demosthenes E. Ziogas
Peripheral General Hospital of Ioannina - Xatzikosta
Read the Original
This page is a summary of: Genome-based diagnostics and predictive tools: a new epoch for breast cancer management, Future Oncology, October 2012, Future Medicine,
DOI: 10.2217/fon.12.115.
You can read the full text:
Contributors
The following have contributed to this page
